Find a Clinical Trial

Showing 31 - 40 of 237 Trials

A Randomized Phase III Trial of Pre-Operative Compared to Post-Operative Stereotactic Radiosurgery in Patients with Resectable Brain Metastases

Principal Investigator:

Tony J. Wang, MD, FASTRO

Contact Number:

212-342-5162

NCT Number:

NCT05438212

Population:

Adult

Phase:

III

The purpose of this study is to compare the usual treatment of having SRS after surgery to receiving SRS before surgery (the study approach). Receiving SRS before surgery could increase the time without your cancer returning or worsening. If you decide to take part in this study, you will be assigned to one of two groups. Half the participants will be assigned to one group and half to a second group. Participants in both groups will get a type of radiation called stereotactic radiosurgery (SRS). SRS delivers a high dose of radiation only to the small areas of cancer in the brain and avoids...
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide with ContinuedVersus Intermittent Androgen-Deprivation Therapy (ADT) following PSA Response inParticipants with Metastatic Castration-Sensitive Prostate Cancer (mCSPC)

Principal Investigator:

Karie Danielle Keera Runcie, MD

Contact Number:

212-342-5162

NCT Number:

NCT05884398

Population:

Adult

Phase:

III

The purpose of this study is to help researchers understand more about the possible effectiveness and safety of apalutamide when given to patients with or without intermittent Androgen Deprivation Therapy (ADT) to treat metastatic Castration-Sensitive Prostate Cancer (mCSPC). Apalutamide is a type of drug that blocks the action of testosterone. By blocking the action of testosterone, it may slow down or stop the growth of prostate cancer cells. ADT works by stopping the body’s production of testosterone. The reason for using ADT is that prostate cancer needs androgen to grow and survive...
A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared with Venetoclax Plus Obinutuzumab in Patients with Previously UntreatedChronic Lymphocytic Leukemia

Principal Investigator:

Nicole Lamanna, MD

Contact Number:

212-342-5162

NCT Number:

NCT06073821

Population:

Adult

Phase:

III

The purpose of study is to compare the effectiveness of two combinations of anticancer study drugs in treating your chronic lymphocytic leukemia (CLL). The first combination is sonrotoclax (also known as BGB-11417) and zanubrutinib, while the second combination is venetoclax and obinutuzumab. Sonrotoclax and zanubrutinib are investigational drugs developed by BeiGene (the sponsor). Sonrotoclax has not been approved for treatment by the United States Food and Drug Administration (FDA). Zanubrutinib has been approved for the treatment of certain blood cancers by the FDA. However, it is still...
A Randomized Phase III Trial of Intravesical BCG veRsus Intravesical Docetaxel and GEmcitabine Treatment in BCG Naïve High-Grade Non-Muscle Invasive Bladder Cancer (BRIDGE)

Principal Investigator:

Andrew T Lenis, MD

Contact Number:

212-342-5162

NCT Number:

NCT05538663

Population:

Adult

Phase:

III

This study is being done to answer the following question: Can we lower the chance of your bladder cancer growing or spreading by using one type of chemotherapy instilled in the bladder, Gemcitabine and Docetaxel, instead of the usual therapy? The usual approach for patients who are not in a study is treatment with Transurethral surgery of bladder tumor (TURBT) followed by instillations of Bacillus Calmette-Guerin (BCG) immunotherapy into the bladder via a catheter. We are doing this study because we want to find out if this approach is better or worse than the usual approach for your bladder...
A Phase 3, Multicenter, Open-label Study to Test the Diagnostic Performance of Copper Cu 64 PSMA IT PET/CT in Staging of Men with Newly Diagnosed Unfavorable Intermediate-risk, High-risk or Very High-risk Prostate Cancer Electing to Undergo Radical

Principal Investigator:

Mark N. Stein, MD

Contact Number:

212-342-5162

NCT Number:

NCT06235151

Population:

Adult

Phase:

III

The purpose of this research study is to see how safe and effective the use of copper Cu 64 PSMA I&T Injection is in imaging prostate cancer tumors for staging of men with newly diagnosed intermediate or high risk prostate cancer. Copper Cu 64 PSMA I&T Injection is an investigational imaging agent, given to you through your vein (intravenous (IV)), that makes tumors from prostate cancer show up during a nuclear medicine imaging scan. The imaging scan is a type of nuclear medicine imaging test, which means it uses a radioactive drug (a drug that contains a radioactive substance and is...
A Randomized, Open-label Phase 3 Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer

Principal Investigator:

Yoanna S Pumpalova, MD

Contact Number:

212-342-5162

NCT Number:

NCT06662786

Population:

Adult

Phase:

III

The purpose of this study is to compare the effects of two anticancer drugs (amivantamab and cetuximab) when each is given in combination with standard colorectal cancer (CRC) chemotherapies to participants with metastatic (cancerous) CRC that lack mutations in genes called KRAS/NRAS and BRAF. Amivantamab is an investigational drug in this study, meaning it is currently being tested and has not been approved by the United States Food and Drug Administration (FDA) for your disease. This is why amivantamab is being compared with cetuximab, an FDA-approved treatment, to evaluate its efficacy and...
A Phase 3 Open-Label, Randomized Study of LOXO-305 versus Investigator Choice of BTK Inhibitor in Patients with Previously Treated BTK Inhibitor Naïve Mantle Cell Lymphoma (BRUIN MCL-321)

Principal Investigator:

Andrew H Lipsky, MD

Contact Number:

212-342-5162

NCT Number:

NCT04662255

Population:

Adult

Phase:

III

This research study is being done to test the effectivenss and safety of an investigational treatment called LOXO-305. LOXO-305 is an investigational (or experimental) drug that may treat certain cancers like leukemia and lymphomas, including, mantle cell lymphoma (MCL). These cancers are dependent on or “addicted to” a protein made by the cancers called “BTK”. LOXO-305 is a “BTK inhibitor”—it is designed to block both normal and mutated forms of BTK in these cancers. Are you Eligible? (Inclusion Criteria) At least 18 years of age Able to swallow oral...
A Phase III Randomized Trial For Newly Diagnosed Multiple Myeloma (NDMM) Patients Considered Frail Or In A Subset of “Intermediate Fit” Comparing Upfront Three-Drug Induction Regimens Followed by Double- or Single-Agent Maintenance

Principal Investigator:

Divaya Bhutani, MD

Contact Number:

212-342-5162

NCT Number:

NCT05561387

Population:

Adult

Phase:

III

The purpose of this study is to compare the usual treatment plan to using a different combination of drugs. Researchers will test a different combination of drugs called DRd. DRd combines 3 drugs for treatment: daratumumab and hyaluronidase, lenalidomide, and dexamethasone. Using the study treatment instead of the usual treatment could reduce or control the cancer better. The study treatment may also cause side effects which the doctors will be watching for. This study will help the study doctors learn which combination of drugs is better among the usual treatments for multiple myeloma...
A Randomized, Double-blind, Placebo-controlledPhase 3 Study to evaluate Dostarlimab as SequentialTherapy after Chemoradiation in Participants withLocally Advanced Unresected Head and NeckSquamous Cell Carcinoma

Principal Investigator:

Brian Henick, MD

Contact Number:

212-342-5162

NCT Number:

NCT06256588

Population:

Adult

Phase:

III

The purpose of this study is to find out if an experimental drug, which is not approved by the United States Food and drug Administration, called dostarlimab given over the course of 1 year starting shortly after chemoradiotherapy (CRT) has finished, can delay or reduce the risk of cancer returning when compared to placebo given over the same time period following CRT. The experimental drug is being tested in participants with locally advanced unresected head and neck squamous cell carcinoma. Dostarlimab belongs to a class of drugs called PD-1 inhibitors. The immune cells in your body produce...
A Phase 3, Randomized, Double-blind, Placebo- and Active-Comparator- Controlled Clinical Studyof Adjuvant V940 (mRNA-4157) Plus Pembrolizumab Versus Adjuvant Placebo Plus Pembrolizumabin Participants With Resected Stage II, IIIA, IIIB (N2) Non-small Cell

Principal Investigator:

Joshua R. Sonett, MD

Contact Number:

212-342-5162

NCT Number:

NCT06077760

Population:

Adult

Phase:

III

The purpose of this study is to evaluate the safety and effectiveness of the investigational drug V940 in combination with pembrolizumab for preventing relapse in non-small cell lung cancer. V940 is not yet approved by the U.S. Food and Drug Administration (FDA), which means it is still under investigation and has not been authorized for general use. Pembrolizumab, however, is an FDA-approved drug commonly used in cancer treatment. This study aims to determine how well V940 and pembrolizumab work together compared to a placebo combined with pembrolizumab. Additionally, it will assess the...

Find a Clinical Trial

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Pages